This phase III trial is comparing a new oral therapy (Selpercatinib) with a standard treatment in patients with advanced non-small cell lung cancer.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Eli Lilly and Company
Eligible patients will be randomised to receive the experimental treatment (Selpercatinib, administered orally) or intravenous Pemetrexed (plus the investigator's discretion of carboplatin or cisplatin) with or without Pembrolizumab.
Recruiting Hospitals Read More